|BioDelivery: Good Time to Buy?|
|By Vinny Cassano|
|Saturday, 19 February 2011 00:00|
Earlier this week, BioDelivery Sciences (NSDAQ:BDSI) announced that the ongoing BEMA Buprenorphine Phase III trial is more than 50% enrolled and is expected to be completed on schedule.
The trial, measuring BEMA Bup for effectiveness in treating chronic pain, began in December of last year and is scheduled to wrap-up later this year, with an expected NDA filing to take place during the first half of 2011.
BioDelivery also has Onsolis on the market in both the US and Canadian markets for the treatment of breakthrough cancer pain. Onsolis sales have currently been hindered by an ongoing REMS issue, but both BDSI and partner Meda have been making headway in discussions with the FDA and it's expected that the ordeal will draw to a close later this year.
With a novel drug delivery system and multiple products in the pipeline, BioDelivery is still one with significant growth potential over the long term. Looks like the low-$3 range is the time to add shares.
As pointed out on Seeking Alpha recently, BDSI is favorably reviewed by analysts with a fairly strong buy rating and a forecasted upside close to double the current price.
Vinny also authors the popular stock investing blog, VFC's Stock House.
Disclosure: Long BDSI